[关键词]
[摘要]
植物药和中国的中药、日本的汉方药、澳大利亚的传统药物等现已成为世界医药的重要组成部分,并且植物药和汉方药的专利保护策略在国际上已经相当成熟。然而,我国中药知识产权的专利保护经验不足,明显落后于植物药专利保护较早的欧洲国家,尤其是德国。以Tebonin®为例,立足研发技术角度,较为深入剖析了德国植物药Tebonin®的专利申请与保护策略。并结合中国中药专利保护现状,给国内制药企业的中药新药研发提供参考和借鉴。
[Key word]
[Abstract]
Herbal medicine and Chinese materia medica (CMM), Kampo, traditional medicine in Australia, and other traditional medicines have been an important part of the world medicine, and the patent protection strategies of herbal medicine and Kampo at the international level have been already quite mature. However, China have less experience in patent protection strategies of CMM, and apparently fall behind the herbal medicine patent protection strategies of European countries, especially Germany. In this paper, based on the perspective of research and development, the patent application and protection strategies of Tebonin® from Germany are analyzed in depth. Considering patent conservation status of CMM, some workable references for the domestic pharmaceutical enterprises of CMM in the field of research and development of new drugs are provided.
[中图分类号]
[基金项目]
工业和信息化部知识产权推进计划项目——陇药及有色金属新材料产业知识产权运用培育(2014020001);甘肃省知识产权计划专项——甘肃省特色农业产业专利创新运营模式研究(1607PIPA060)